AroCell AB (publ) (AROC.ST)
SEK 0.59
(-2.33%)
SEK 0.59
(-2.33%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 6.07 Million SEK | -17.68% |
| 2022 | 7.37 Million SEK | 6.73% |
| 2021 | 6.91 Million SEK | 386.96% |
| 2020 | 1.41 Million SEK | -4.28% |
| 2019 | 1.48 Million SEK | -16.29% |
| 2018 | 1.77 Million SEK | 3.12% |
| 2017 | 1.71 Million SEK | 21.03% |
| 2016 | 1.41 Million SEK | 0.0% |
| 2015 | 1.41 Million SEK | -10.1% |
| 2014 | 1.57 Million SEK | 2.87% |
| 2013 | 1.53 Million SEK | 199.77% |
| 2012 | 511.86 Thousand SEK | -4.6% |
| 2011 | 536.52 Thousand SEK | -27.87% |
| 2010 | 743.85 Thousand SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 7.14 Million SEK | 17.74% |
| 2024 Q2 | 6.1 Million SEK | -14.65% |
| 2024 Q3 | 6.86 Million SEK | 12.59% |
| 2023 Q4 | 6.07 Million SEK | -12.55% |
| 2023 FY | 6.07 Million SEK | -17.68% |
| 2023 Q3 | 6.94 Million SEK | -2.27% |
| 2023 Q2 | 7.1 Million SEK | -10.72% |
| 2023 Q1 | 7.95 Million SEK | 7.88% |
| 2022 Q4 | 7.37 Million SEK | -4.89% |
| 2022 FY | 7.37 Million SEK | 6.73% |
| 2022 Q3 | 7.75 Million SEK | -0.45% |
| 2022 Q2 | 7.78 Million SEK | 13.54% |
| 2022 Q1 | 6.86 Million SEK | -0.72% |
| 2021 Q1 | 1.98 Million SEK | 40.03% |
| 2021 Q4 | 6.91 Million SEK | -1.22% |
| 2021 Q2 | 1.93 Million SEK | -2.77% |
| 2021 Q3 | 6.99 Million SEK | 262.06% |
| 2021 FY | 6.91 Million SEK | 386.96% |
| 2020 Q2 | 1.68 Million SEK | -2.48% |
| 2020 Q1 | 1.73 Million SEK | 16.76% |
| 2020 FY | 1.41 Million SEK | -4.28% |
| 2020 Q3 | 1.76 Million SEK | 4.27% |
| 2020 Q4 | 1.41 Million SEK | -19.38% |
| 2019 Q3 | 1.7 Million SEK | -5.7% |
| 2019 Q4 | 1.48 Million SEK | -13.0% |
| 2019 Q2 | 1.8 Million SEK | 17.72% |
| 2019 Q1 | 1.53 Million SEK | -13.32% |
| 2019 FY | 1.48 Million SEK | -16.29% |
| 2018 Q2 | 1.41 Million SEK | -40.33% |
| 2018 FY | 1.77 Million SEK | 3.12% |
| 2018 Q4 | 1.77 Million SEK | 24.8% |
| 2018 Q3 | 1.41 Million SEK | 0.0% |
| 2018 Q1 | 2.37 Million SEK | 38.46% |
| 2017 Q4 | 1.71 Million SEK | -23.43% |
| 2017 FY | 1.71 Million SEK | 21.03% |
| 2017 Q1 | 1.41 Million SEK | -0.0% |
| 2017 Q2 | 2.24 Million SEK | 58.07% |
| 2017 Q3 | 2.24 Million SEK | 0.0% |
| 2016 FY | 1.41 Million SEK | 0.0% |
| 2016 Q1 | 1.41 Million SEK | -0.0% |
| 2016 Q4 | 1.41 Million SEK | 0.0% |
| 2016 Q3 | 1.41 Million SEK | 0.0% |
| 2016 Q2 | 1.41 Million SEK | 0.0% |
| 2015 Q3 | 1.43 Million SEK | 0.0% |
| 2015 FY | 1.41 Million SEK | -10.1% |
| 2015 Q4 | 1.41 Million SEK | -1.39% |
| 2015 Q1 | 1.41 Million SEK | -10.1% |
| 2015 Q2 | 1.43 Million SEK | 1.41% |
| 2014 Q4 | 1.57 Million SEK | 3.91% |
| 2014 Q3 | 1.51 Million SEK | 0.13% |
| 2014 FY | 1.57 Million SEK | 2.87% |
| 2014 Q2 | 1.51 Million SEK | 5.42% |
| 2014 Q1 | 1.43 Million SEK | -6.22% |
| 2013 Q3 | 362 Thousand SEK | -14.22% |
| 2013 Q4 | 1.53 Million SEK | 323.87% |
| 2013 FY | 1.53 Million SEK | 199.77% |
| 2013 Q1 | 512 Thousand SEK | 0.03% |
| 2013 Q2 | 422 Thousand SEK | -17.58% |
| 2012 Q4 | 511.86 Thousand SEK | 32.27% |
| 2012 Q3 | 387 Thousand SEK | -22.91% |
| 2012 Q1 | 537 Thousand SEK | 0.09% |
| 2012 FY | 511.86 Thousand SEK | -4.6% |
| 2012 Q2 | 502 Thousand SEK | -6.52% |
| 2011 FY | 536.52 Thousand SEK | -27.87% |
| 2011 Q4 | 536.52 Thousand SEK | -31.74% |
| 2011 Q3 | 786 Thousand SEK | 3.15% |
| 2011 Q2 | 762 Thousand SEK | 0.0% |
| 2010 Q4 | 743.85 Thousand SEK | 0.0% |
| 2010 FY | 743.85 Thousand SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Devyser Diagnostics AB (publ) | 20.6 Million SEK | 70.529% |
| Immunovia AB (publ) | 1.00 SEK | -607099900.0% |
| Prostatype Genomics AB (publ) | 203 Thousand SEK | -2890.64% |
| SenzaGen AB | 6.22 Million SEK | 2.521% |
| Spermosens AB | -232 Thousand SEK | 2716.81% |